United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $232.05, for a total transaction of $835,380.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,166.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

United Therapeutics Stock Up 1.5 %

UTHR stock opened at $235.31 on Thursday. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54. The firm has a market cap of $11.07 billion, a PE ratio of 11.86 and a beta of 0.52. The firm has a 50 day simple moving average of $230.70 and a 200 day simple moving average of $228.38. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, beating the consensus estimate of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business had revenue of $614.70 million during the quarter, compared to analyst estimates of $575.01 million. During the same period in the prior year, the business earned $2.67 earnings per share. The business’s quarterly revenue was up 25.1% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Co. will post 23.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on UTHR. Wells Fargo & Company upped their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th. Wedbush reaffirmed an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. SVB Leerink began coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 price target for the company. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $292.67.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently made changes to their positions in the company. Rise Advisors LLC purchased a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $32,000. Atlas Capital Advisors LLC purchased a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $51,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of United Therapeutics by 49.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 65 shares in the last quarter. GAMMA Investing LLC purchased a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $43,000. Finally, Neo Ivy Capital Management purchased a new stake in shares of United Therapeutics in the 2nd quarter valued at approximately $48,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.